BLLN (BillionToOne) Total Liabilities: $195.1 Mil (As of Mar. 2026)


BLLN BillionToOne Inc BLLN
13 GF Score
Price $122.33
! 5 Warning Signs
View Full Analysis

What is BillionToOne Total Liabilities?

BillionToOne BLLN +2.04% 13 Total Liabilities is $195.1 Mil as of Mar. 2026. GuruFocus rates BLLN with a GF Score™ of 13/100. The stock has 5 warning signs investors should review.

BillionToOne's Total Liabilities for the quarter that ended in Mar. 2026 was $195.1 Mil.

BillionToOne's quarterly Total Liabilities declined from Sep. 2025 ($567.03 Mil) to Dec. 2025 ($152.55 Mil) but then increased from Dec. 2025 ($152.55 Mil) to Mar. 2026 ($195.11 Mil).

BillionToOne's annual Total Liabilities increased from Dec. 2023 ($410.73 Mil) to Dec. 2024 ($553.72 Mil) but then declined from Dec. 2024 ($553.72 Mil) to Dec. 2025 ($152.55 Mil).

BillionToOne Total Liabilities Historical Data

* Premium members only.

The historical data trend for BillionToOne's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BillionToOne Total Liabilities Chart

BillionToOne Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
410.73 553.72 152.55

BillionToOne Quarterly Data
Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 0.00 562.89 567.03 152.55 195.11
BLLN
13GF Score
BillionToOne Inc BLLN
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BillionToOne Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

BillionToOne's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=47.962+(103.297+6.2172489379009E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+1.29+0+0)
=152.5

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=632.654-480.105
=152.5

BillionToOne's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=57.162+(137.945+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=195.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=700.727-505.62
=195.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $195.1 Mil mean?
BillionToOne (BLLN) has a Total Liabilities of $195.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BillionToOne and its competitors.
Is BillionToOne's Total Liabilities too high?
BillionToOne's current Total Liabilities is $195.1 Mil. Overall, BillionToOne has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does BillionToOne's Total Liabilities compare to SHC and VCYT?
BillionToOne's Total Liabilities of $195.1 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for BillionToOne and its competitors. BillionToOne's current Total Liabilities is $195.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BillionToOne stock overvalued right now?
BillionToOne (BLLN) has a current Total Liabilities of $195.1 Mil. The current Total Liabilities is $195.1 Mil. BillionToOne's overall GF Score™ is 13/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For BillionToOne (BLLN), the current Total Liabilities is $195.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BillionToOne Business Description

Address 1035 O’Brien Drive, Menlo Park, CA, USA, 94025
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
13GF Score

Get the complete analysis for BLLN

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$122.33
Price